Genentech: Press Releases | Tuesday, Jul 16, 2024
WEBJul 16, 2024 · Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both …
Roche's oral obesity drug leads to weight loss in early study - STAT
WEBJul 17, 2024 · The company said its once-daily pill, called CT-996, led to a placebo-adjusted average weight loss of 6.1% after four weeks in patients with obesity who did not have diabetes.
Roche touts early trial success of second obesity drug candidate
WEBJul 17, 2024 · Roche's experimental once-daily pill CT-996 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in a Phase I trial, Roche said in a...
Roche says early-stage obesity pill results were based on just six ...
WEB4 days ago · The Swiss drugmaker said in July that the once-daily pill CT-996 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in a Phase I trial.
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
WEBJul 17, 2024 · RHHBY announced positive top-line results from an early-stage study on its experimental obesity candidate CT-996. The study is a multi-part, multi-cohort phase I randomized, double-blind,...
Genentech Announces Positive Phase I Results of Its Oral
WEBJul 17, 2024 · CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity, currently in Phase I, with the...
News - Carmot Therapeutics
WEBOct 10, 2023 · CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). CT-996 was designed to exhibit signaling bias on the GLP-1 receptor, resulting in activation of cAMP with minimal to no recruitment of ß-arrestin.
Roche reports positive data from Phase I obesity treatment trial
WEBJul 17, 2024 · Roche has reported positive topline data from the ongoing multi-part Phase I clinical trial of CT-996, an oral GLP-1 receptor agonist, to treat type 2 diabetes (T2D) and obesity.
Roche Announces Positive Phase I Results Of CT-996 For
WEBJul 17, 2024 · Roche announced positive results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.
Roches Investigational Oral GLP-1 Receptor Agonist CT-996 …
WEBAug 27, 2024 · Basel, 17 July 2024 - Roche, a leading global pharmaceutical company, has recently unveiled positive topline results from its Phase I clinical trial for CT-996, an innovative oral small molecule GLP-1 receptor agonist.
Skip to content